Movatterモバイル変換

[0]ホーム
URL:

JPS5599189A - Modified uricase free from antigenicity and its preparation - Google Patents

Modified uricase free from antigenicity and its preparation

Info

Publication number
JPS5599189A
JPS5599189AJP578779AJP578779AJPS5599189AJP S5599189 AJPS5599189 AJP S5599189AJP 578779 AJP578779 AJP 578779AJP 578779 AJP578779 AJP 578779AJP S5599189 AJPS5599189 AJP S5599189A
Authority
JP
Japan
Prior art keywords
uricase
antigenicity
preparation
free
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP578779A
Other languages
Japanese (ja)
Inventor
Yuji Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIHAMA HISAHARU
Original Assignee
MIHAMA HISAHARU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIHAMA HISAHARUfiledCriticalMIHAMA HISAHARU
Priority to JP578779ApriorityCriticalpatent/JPS5599189A/en
Publication of JPS5599189ApublicationCriticalpatent/JPS5599189A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

PURPOSE: To prepare a modified uricase usable for treating patients with hyperuricemia, having a low or no antigenicity, by substituting 30% or more of amino groups in the uricase molecule with long-chain high polymer residues.
CONSTITUTION: Uricase is reacted with an 2-O-substituted-polyethylene glycol-4, 6-dichloro-s-triazine, e.g. 2-O-methoxypolyethylene glycol-4,6-dichloro-s-triazine, having a molecular weight ≥2,000 to give a modified uricase wherein 30% or more of amino groups in the uricase molecule are substituted by groups of the formula (R is water-soluble high polymer residue, e.g. O-methoxypolyethylene glycol residue, having a molecular weight ≥2,000).
COPYRIGHT: (C)1980,JPO&Japio
JP578779A1979-01-221979-01-22Modified uricase free from antigenicity and its preparationPendingJPS5599189A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
JP578779AJPS5599189A (en)1979-01-221979-01-22Modified uricase free from antigenicity and its preparation

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
JP578779AJPS5599189A (en)1979-01-221979-01-22Modified uricase free from antigenicity and its preparation

Publications (1)

Publication NumberPublication Date
JPS5599189Atrue JPS5599189A (en)1980-07-28

Family

ID=11620804

Family Applications (1)

Application NumberTitlePriority DateFiling Date
JP578779APendingJPS5599189A (en)1979-01-221979-01-22Modified uricase free from antigenicity and its preparation

Country Status (1)

CountryLink
JP (1)JPS5599189A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS57192435A (en)*1981-05-201982-11-26Toyobo Co LtdModified polypeptide
WO2006110819A2 (en)2005-04-112006-10-19Savient Pharmaceuticals, Inc.Variant forms of urate oxidase and use thereof
US7229810B2 (en)2001-06-282007-06-12Mountain View Pharmaceuticals, Inc.Polymer conjugates of proteinases
EP2158923A1 (en)1998-08-062010-03-03Mountain View Pharmaceuticals, Inc.Peg-urate oxidase conjugates and use thereof
US7811800B2 (en)2005-04-112010-10-12Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US7927852B2 (en)1998-08-062011-04-19Mountain View Pharmaceuticals, Inc.Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US8129330B2 (en)2002-09-302012-03-06Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8148123B2 (en)2005-04-112012-04-03Savient Pharmaceuticals, Inc.Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP2535347A1 (en)2002-09-302012-12-19Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9534013B2 (en)2006-04-122017-01-03Horizon Pharma Rheumatology LlcPurification of proteins with cationic surfactant
US11598767B2 (en)2009-06-252023-03-07Horizon Therapeutics Usa, Inc.Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
JP2023548496A (en)*2020-11-032023-11-17プロタリクス リミテッド Modified uricase and its use

Cited By (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS57192435A (en)*1981-05-201982-11-26Toyobo Co LtdModified polypeptide
US9885024B2 (en)1998-08-062018-02-06Duke UniversityPEG-urate oxidase conjugates and use thereof
EP2158923A1 (en)1998-08-062010-03-03Mountain View Pharmaceuticals, Inc.Peg-urate oxidase conjugates and use thereof
US8921064B2 (en)1998-08-062014-12-30Mountain View Pharmaceuticals, Inc.Method for purifying urate oxidase tetramers and octamers
US7927852B2 (en)1998-08-062011-04-19Mountain View Pharmaceuticals, Inc.Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7927589B2 (en)1998-08-062011-04-19Mountain View Pharmaceuticals, Inc.PEG-urate oxidase conjugates and use thereof
EP2316475A1 (en)1998-08-062011-05-04Mountain View Pharmaceuticals, Inc.Isolated tetrameric uricase
US8618267B2 (en)1998-08-062013-12-31Mountain View Pharmaceuticals, Inc.PEG-urate oxidase conjugates and use thereof
US8067553B2 (en)1998-08-062011-11-29Mountain View Pharmaceuticals, Inc.PEG-urate oxidase conjugates and use thereof
US7229810B2 (en)2001-06-282007-06-12Mountain View Pharmaceuticals, Inc.Polymer conjugates of proteinases
EP2535347A1 (en)2002-09-302012-12-19Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en)2002-09-302012-03-06Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7964381B2 (en)2005-04-112011-06-21Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US8034594B2 (en)2005-04-112011-10-11Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US8188224B2 (en)2005-04-112012-05-29Savient Pharmaceuticals, Inc.Variant forms of urate oxidase and use thereof
US8293228B2 (en)2005-04-112012-10-23Savient Pharmaceuticals Inc.Variant form of urate oxidase and use thereof
US8148123B2 (en)2005-04-112012-04-03Savient Pharmaceuticals, Inc.Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8465735B2 (en)2005-04-112013-06-18Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US8541205B2 (en)2005-04-112013-09-24Savient Pharmaceuticals, Inc.Variant forms of urate oxidase and use thereof
US11781119B2 (en)2005-04-112023-10-10Horizon Therapeutics Usa, Inc.Variant forms of urate oxidase and use thereof
US7811800B2 (en)2005-04-112010-10-12Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US9017980B2 (en)2005-04-112015-04-28Crealta Pharmaceuticals LlcVariant forms of urate oxidase and use thereof
EP2947145A1 (en)2005-04-112015-11-25Crealta Pharmaceuticals LLCVariant forms of urate oxidase and use thereof
US8178334B2 (en)2005-04-112012-05-15Savient Pharmaceuticals, Inc.Variant form of urate oxidase and use thereof
US9670467B2 (en)2005-04-112017-06-06Horizon Pharma Rheumatology LlcVariant forms of urate oxidase and use thereof
WO2006110819A2 (en)2005-04-112006-10-19Savient Pharmaceuticals, Inc.Variant forms of urate oxidase and use thereof
EP3321359A1 (en)2005-04-112018-05-16Crealta Pharmaceuticals LLCVariant forms of urate oxidase and use thereof
US9534013B2 (en)2006-04-122017-01-03Horizon Pharma Rheumatology LlcPurification of proteins with cationic surfactant
US11639927B2 (en)2009-06-252023-05-02Horizon Therapeutics Usa, Inc.Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11598767B2 (en)2009-06-252023-03-07Horizon Therapeutics Usa, Inc.Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11982670B2 (en)2009-06-252024-05-14Horizon Therapeutics Usa, Inc.Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US12188927B2 (en)2009-06-252025-01-07Horizon Therapeutics Usa, Inc.Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
JP2023548496A (en)*2020-11-032023-11-17プロタリクス リミテッド Modified uricase and its use

Similar Documents

PublicationPublication DateTitle
JPS5599189A (en)Modified uricase free from antigenicity and its preparation
EP0310321A3 (en)Immunomodulatory azaspiranes
MD1233B1 (en)Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
JPS55138393A (en)Semisynthesis of insulin
PT79840A (en)Process for the preparation of polipeptides with alpha-amilase inhibiting action and pharmaceutical compositions therewith
WO1987004426A3 (en)Vinyl compositions
YU89691A (en) PROCEDURE FOR OBTAINING STEREOSELECTIVE DERIVATIVES OF PHENYLISOSERIN
AU3923789A (en)Diorganopolysiloxane derivatives, their preparation and their use
ES8103027A1 (en)Tripeptides, process for their preparation, therapeutic compositions containing them and methods for their use.
NO800724L (en) PROCEDURE FOR PREPARING PEPTIDES WITH UBIQUIT-SIMILAR ACTIVITY
ES2008962A6 (en)New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process.
JPS5219754A (en)Preparation of crosslinked epihalohydrin polymer composition
UA41871C2 (en)Derivatives of erythromycin, a process for the preparation thereof and a pharmaceutical composition based thereon
ES2001389A6 (en)Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors.
IL94703A0 (en)Thienopyran derivatives,their preparation and pharmaceutical compositions containing them
LTIP577A (en)Novel pilocarpine derivatives and process for their preparation
CA2049837A1 (en)Powder coating compositions
JPS5559151A (en)Aminoacid derivative
JPS55138392A (en)Semisynthesis of insulin
JPS51125471A (en)Preparation of high molecular weight polymers resistant to oxidation
JPS5419947A (en)Chalcone derivatives
JPS5440894A (en)Cinchona-alkaloid-acrylonitrile copolymer and its preparation
JPS5236185A (en)Preparation of novel reactive polymer
JPS54106481A (en)Novel 2,3-dioxopiperazine derivative and its preparation
JPS5371093A (en)Benzothiepin derivs. and process for their preparation
[8]ページ先頭
©2009-2025 Movatter.jp